A mysterious RNA found in breast cancer led scientists to uncover an entire hidden class of cancer-specific RNAs across ...

Grail continues facing significant challenges as its stock plummeted over 45% after its landmark NHS-Galleri trial failed to ...

GRAIL, Inc. , a healthcare company whose mission is to detect cancer early when it can be cured, today announced topline results from the landmark, randomized, controlled NHS-Galleri trial, which ...

Khaberni - Early cancer detection technologies are undergoing a radical transformation with the emergence of multicancer blood tests (MCED), which rely on the analysis of free DNA ...

BIOPREVENT’ AI tool predicts transplant-related immune conflict and mortality risk using biomarkers, helping doctors ...

Background and objectives Lung cancer remains the leading cause of cancer-related mortality worldwide. Early detection of pulmonary nodules is crucial for timely diagnosis and effective treatment.

GRAIL reported that 2025 total revenue rose 17% year on year to $147.2 million, driven by a 26% increase in U.S. Galleri sales to $136.8 million, while net loss narrowed sharply to $408.4 million and ...

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter and full year ...

Nikki Romanik and Ashish K Jha propose a new surveillance system to detect and attribute emerging biological threats to enable a rapid public health response Recent advances in bioengineering ...

Insulin resistance - when the body doesn't properly respond to insulin, a hormone that helps control blood glucose levels - ...

A recent study suggests that a freely available AI tool could help predict dangerous complications after stem cell transplants.